Trials / Completed
CompletedNCT04778878
Assessment of Chemotherapy-induced Peripheral Neurotoxicity Using a Point-of-care Nerve Conduction Study Device
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 12 (actual)
- Sponsor
- Oulu University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the feasibility of the Mediracer® NCS device in early detection of CIPN in patients receiving potentially neurotoxic substance (vincristine, oxaliplatin or docetaxel) as a part of their chemotherapy regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Mediracer® NCS | A point-of-care, hand-held nerve conduction device |
Timeline
- Start date
- 2019-10-01
- Primary completion
- 2021-02-28
- Completion
- 2021-02-28
- First posted
- 2021-03-03
- Last updated
- 2025-08-24
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT04778878. Inclusion in this directory is not an endorsement.